Ishii Hiromasa
Division of Gastroenterology, Department of Internal Medicine, School of Medicine, Keio University.
Nihon Rinsho. 2006 Jun;64(6):1017-9.
In Japan, much attention has been paid to NASH and NAFLD for the past several years and the prevalence of this disease entity has been estimated, and NASH is thought to be present in 10% of those who have fatty liver diseases. Other points out the prevalence of NASH in Japan as 6 to 8 hundred thousand patients. The last two or three decades have seen the evolution of Western-style life of near complete inactivity, energy-dense food choices and liberal fiscal resources to obtain them and other means to avoid physical activity. Moreover, what is increasingly apparent is that NASH and NAFLD is not a Western disease and many population groups in the Asia-Pacific region are particularly prone to type 2 diabetes. Thus, it is not surprising that NASH has increasingly been diagnosed in several regions in Asia including Indonesia, Malaysia, Philippines, Thailand and India.
在日本，过去几年里非酒精性脂肪性肝炎（NASH）和非酒精性脂肪性肝病（NAFLD）受到了广泛关注，人们对这种疾病实体的患病率进行了估算，据认为在患有脂肪性肝病的人群中，10%患有NASH。还有人指出，日本NASH患者人数为60万至80万。在过去的二三十年里，西方生活方式逐渐演变，人们几乎完全不活动，选择高能量食物，并有充足的资金获取这些食物以及采用其他方式避免体育活动。此外，越来越明显的是，NASH和NAFLD并非西方疾病，亚太地区的许多人群尤其容易患2型糖尿病。因此，在包括印度尼西亚、马来西亚、菲律宾、泰国和印度在内的亚洲多个地区，NASH的诊断病例越来越多也就不足为奇了。
